Abstract 4558
Background
Response of desmoid tumors (DT) to chemotherapy (CT) is evaluated according to RECIST criteria in daily practice and clinical trials. However, MRI demonstrates early change in heterogeneity in responding tumor, due to decrease in cellular area and increase in fibro-necrotic content, before dimensional response. Heterogeneity can be quantified through radiomics approach. Aim was to develop radiomics-based response criteria and to compare their performances with usual criteria.
Methods
43 patients (28 women, median age: 38.2) were prospectively included in this ancillary multicentre study of a randomized phase II trial (NCT01876082) as they presented with progressive DT, contrast-enhanced MRI at baseline (MRI-0) and early evaluation (3 months later, MRI-1). After signal intensities normalization, voxel size standardization and segmentation of whole DT volume on fat-suppressed contrast-enhanced T1-weighted imaging, 90 baseline and delta 3D-radiomics features (RF) were extracted. Using least absolute shrinkage and selection operator with Cox regression model and cross validation, a radiomics score based on selected and weighted RF was generated. The performances of prognostic models based on radiomics score, RECIST, mRECIST, EASL, Cheson, Choi and modified-Choi criteria from MRI-0 to MRI-1 to predict progression-free survival (PFS) were assessed with concordance-index. All the results were adjusted for ECOG performance status, initial tumor volume, prior CTs, current CT and B-catenin mutation. Usual response criteria were evaluated in both disease control and objective response settings.
Results
There were 11 progressions. The radiomics score included 4 variables (1 baseline RF and 3 delta-RF). A high radiomics score indicated a poorer prognosis. The radiomics score significantly correlated with PFS (adjusted hazard ratio = 3.39, 95%CI = [1.47-7.79], p = 0.0043) while none of the usual response criteria was (range of p-values = [0.166-0.750]). The prognostic model based on radiomics score had the highest concordance-index (0.794, 95%CI = [0.678-0.910]).
Conclusions
Quantifying heterogeneity with MRI at baseline and its early change through a dedicated radiomics score can improve the response evaluation for DT treated with CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Antoine Italiano.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract